Celebrating 10 Years of Trusted News Discovery
One News Page
> >

Orthocell completes CelGro study accelerating dental implant treatments

Proactive Investors Thursday, 20 June 2019
Orthocell Ltd (ASX:OCC) has completed the CelGro® single-stage dental implant study designed to assess effectiveness and predictability in accelerating treatment timeframes. The marketing study follows the successful two-stage dental implant trial and market authorisation of CelGro in the European Union for dental bone and soft tissue applications. Study results further validate CelGro as a superior medical device for bone and soft tissue repair and will assist in driving market adoption. “CelGro as the best in class collagen membrane” Orthocell’s managing director Paul Anderson said: “CelGro’s ability to deliver superior bone growth has the potential to revolutionise dental implant techniques and is highly desired by physicians and potential partners. “The latest results provide further evidence that positions CelGro as the best in class collagen membrane.” The 10 patients treated in the marketing study had previously suffered, in some cases for many years, from damaged, missing or diseased teeth. Symptoms prior to treatment included severe irritation, bleeding gums, an inability to chew or eat certain foods and enjoy a normal diet. Treatment completion in four months After surgery with CelGro the impact on patients’ lives was ‘significant’ with patients having successfully generated enough new bone to stabilise their implants and complete treatment in about four months. This is almost half the time of the usual two-stage dental implant treatment. The performance study underpins the compatibility and versality of CelGro as a platform technology and highlights the potential to extend the company’s innovative dental product range. Orthocell is also leveraging the EU regulatory approval and finalising its submission for US regulatory clearance.  
Credit: Wibbitz Studio - Published < > Embed
News video: Dogs Can Detect Lung Cancer With 97% Accuracy

Dogs Can Detect Lung Cancer With 97% Accuracy 01:26

Dogs Can Detect Lung Cancer With 97% Accuracy In a new study, researchers used three beagles to sniff out different blood samples. The report can be found in 'The Journal of the American Osteopathic Association.' The dogs were first trained for two months to give signs if they detected cancer from...

You Might Like

Recent related videos from verified sources

Study Says Petting Dogs or Cats Can Reduce Stress [Video]Study Says Petting Dogs or Cats Can Reduce Stress

Study Says Petting Dogs or Cats Can Reduce Stress A study commissioned by Washington State University has found that comfort from an animal can have a “significant impact” on stress levels. In..

Credit: Wibbitz Top Stories     Duration: 01:10Published

The Number of Americans Who Never Eat Breakfast [Video]The Number of Americans Who Never Eat Breakfast

A study examining people's breakfast preferences found that the average American reported only eating breakfast three times a week typically. In fact, 13 percent admitted they rarely, if ever, eat..

Credit: SWNS STUDIO     Duration: 00:39Published

More Than Half of Men Ashamed of Their Body Hair [Video]More Than Half of Men Ashamed of Their Body Hair

Over half of men admit to feeling "embarrassed" about their body hair, new research has found. The fascinating statistic emerged in a survey of 2,000 men which found that 55 percent of all respondents..

Credit: SWNS STUDIO     Duration: 01:05Published

'Traffic light' food labeling lead to healthier food choices, study finds [Video]'Traffic light' food labeling lead to healthier food choices, study finds

BOSTON — A new study by Massachusetts General Hospital has found that using "traffic light" colors — red, yellow and green — in labeling food items results in healthier food choices. The study..

Credit: TomoNews US     Duration: 01:28Published

Recent related news from verified sources

When hurricanes halt treatment, lung cancer patients die sooner

(Reuters Health) - Lung cancer patients whose radiation treatments are halted by hurricanes or other natural disasters may not live as long as patients who...

Root Canal Work Not So Bad After All

Root canal work is not as bad as people think when compared to other dental procedures. Self-reporting of their dental health suggests that patients find the...
Eurasia Review

Avalon GloboCare launches first-in-human study of AVA-001 for leukemia, non-Hodgkin lymphoma

Avalon GloboCare Corp (NASDAQ:AVCO) on Monday provided an update of four clinical programs in cellular therapy, noting that AVA-001 entered into this month the...
Proactive Investors

Seelos Therapeutics files new drug application for a Sanfilippo syndrome study

Seelos Therapeutics Inc (NASDAQ:SEEL) is one step closer to launching a Phase 2b/3 clinical study for the treatment of Sanfilippo syndrome. The company has filed...
Proactive Investors Also reported by •Business Wire

Other recent news in Business

'The LION KING' smashed July opening records with $185 million in first weekendJP Morgan's MICHAEL Cembalest believes the leveraged loan market is 'deeply concerning' right now
Environmentally friendly: One News Page is hosted on servers powered solely by renewable energy
© 2019 One News Page Ltd. All Rights Reserved.
About us  |  Contact us  |  Disclaimer  |  Press Room  |  Terms & Conditions  |  Content Accreditation
 RSS  |  News for my Website  |  Free news search widget  |  In the News  |  DMCA / Content Removal  |  Privacy & Data Protection Policy
How are we doing? FeedbackSend us your feedback  |   LIKE us on Facebook   FOLLOW us on Twitter  •  FOLLOW us on Pinterest
One News® is a registered trademark of One News Page Ltd.